Related Experiment Videos
Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific
D S Reed1, P Romero, D Rimoldi
1Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland.
Abstract:
The finding that many human melanomas express distinct antigens that can be recognised by specific cytolytic T lymphocytes (CTL) implies that immunotherapeutic strategies against this cancer might prove effective. The ex vivo delivery of a tumour-associated antigen to autologous cells and the subsequent re-administration of these cells to the patient might prove effective in boosting the T cell immune response. Recombinant human adenoviral vectors provide an efficient delivery system and have many advantages over other viral and non-viral delivery vehicles. Infection of a panel of human melanoma cell lines by AdCMVMAGE-1, a novel recombinant adenovirus which incorporates the full-length MAGE-1 cDNA, was shown to induce production of high levels of MAGE-1 protein. Incubation of transduced HLA-A1 expressing melanoma cell lines with 2 anti-MAGE-1.A1 CTL clones resulted in specific recognition and lysis of target cells, indicating that the exogenous MAGE-1 protein was processed and presented in a normal manner. Furthermore, quantitative analyses demonstrated a correlation between the efficiency of transduction and the proportion of cells lysed. Importantly for future clinical trials, stimulation of peripheral blood lymphocytes (PBLs) from a melanoma patient by AdCMVMAGE-1-transduced autologous cells resulted in the generation of specific CTLs against the MAGE-1 antigen. Together, our data emphasize the utility of adenoviruses as vaccination vehicles and highlight the potential efficacy of this approach for the treatment of melanoma.
Insights
This study shows that adenoviruses can effectively deliver MAGE-1 antigen to melanoma cells, stimulating a targeted T cell response. This approach holds promise for developing new melanoma immunotherapies.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Human melanomas express tumor-associated antigens recognized by cytotoxic T lymphocytes (CTLs).
- Immunotherapeutic strategies targeting these antigens may be effective for melanoma treatment.
- Ex vivo antigen delivery to autologous cells can boost T cell responses.
Purpose of the Study:
- To evaluate the efficacy of a novel recombinant adenovirus (AdCMVMAGE-1) for delivering the MAGE-1 antigen to melanoma cells.
- To assess the ability of AdCMVMAGE-1-transduced cells to stimulate specific CTL responses in melanoma patients.
Main Methods:
- Infection of human melanoma cell lines with AdCMVMAGE-1.
- Incubation of transduced cells with anti-MAGE-1.A1 CTL clones.
- Stimulation of peripheral blood lymphocytes (PBLs) from melanoma patients with AdCMVMAGE-1-transduced autologous cells.
Main Results:
- AdCMVMAGE-1 efficiently transduced melanoma cells and induced high levels of MAGE-1 protein expression.
- Transduced cells were specifically recognized and lysed by anti-MAGE-1.A1 CTL clones.
- PBLs from a melanoma patient generated specific CTLs against MAGE-1 after stimulation with transduced autologous cells.
Conclusions:
- Recombinant adenoviruses are effective vaccination vehicles for cancer immunotherapy.
- This approach shows potential for the clinical treatment of melanoma by generating antigen-specific CTLs.